Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             191 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A Chart Review of Lower Dosing of Ponatinib in Patients with Chronic Myeloid Leukemia (CML): Preliminary Findings Mauro, Michael
 2016
 16 S2 p. S57-S58
2 p.
 artikel
2 Acute Tubular Necrosis Secondary to Tyrosine Kinase Inhibitor, Dasatinib, in Philadelphia Chromosome Positive ALL and a Review of the Literature Sarkissian, Sarmen
 2016
 16 S2 p. S1-S3
3 p.
 artikel
3 A Dendritic Cell-Based Vaccine for CLL in Mice: Targeting the CDR3 Domain of B Cell Receptor Rovida, Alessandra
 2016
 16 S2 p. S49-
1 p.
 artikel
4 Adoption of Pediatric-Inspired ALL Regimens by Adult Oncologists Treating Adolescents and Young Adults: A Population-Based Study Muffly, Lori
 2016
 16 S2 p. S3-
1 p.
 artikel
5 Allogeneic Hematopoietic Stem Cell Transplantation in Mantle Cell Lymphoma: a Single Institution Experience Sandoval-Sus, Jose
 2016
 16 S2 p. S115-S116
2 p.
 artikel
6 Altered Expression of IARS (isoleucyl-tRNA synthetase) Genes in Leukemia Mitra, Sanga
 2016
 16 S2 p. S119-
1 p.
 artikel
7 Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in General Community: a Single-Center Experience Ali, Naveed
 2016
 16 S2 p. S52-S53
2 p.
 artikel
8 Analysis of Quality of Life and Well-being from the Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Older Patients with Treatment-naïve CLL (RESONATE-2TM) Kipps, Thomas
 2016
 16 S2 p. S46-
1 p.
 artikel
9 Anaplastic Large Cell Lymphoma in Adults: Results and New Approach of Treatment Gorenkova, Liliia
 2016
 16 S2 p. S110-
1 p.
 artikel
10 A Nationwide Observational Study of Ponatinib in CML Patients Outside of Clinical Trials- The Israeli Experience Amiati, Irina
 2016
 16 S2 p. S64-
1 p.
 artikel
11 Andrographolide Pre-treatment Enhances the Anti-tumor Activity of Topotecan on Acute Myeloid Leukemia Cells In Vitro Rizk, Sandra
 2016
 16 S2 p. S39-
1 p.
 artikel
12 Anemic Outcome Reporting Consistency: Evidence of Selective Reporting Bias in Leading Hematology Journals Wayant, Cole
 2016
 16 S2 p. S129-
1 p.
 artikel
13 Anemic Use of Publication Bias Assessments in Hematology Systematic Reviews: a Chronic Disease Wayant, Cole
 2016
 16 S2 p. S126-
1 p.
 artikel
14 An International Multicenter Project on Secondary Myelofibrosis Mora, Barbara
 2016
 16 S2 p. S91-
1 p.
 artikel
15 A Novel In Situ Vaccine: Intratumoral Flt3L and Poly-ICLC with Low-Dose Radiotherapy Marron, Thomas
 2016
 16 S2 p. S97-S98
2 p.
 artikel
16 Antibacterial Prophylaxis Reduces the Risk of Bacteremia in Patients with Multiple Myeloma and Lymphoma Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplantation Shargian-Alon, Liat
 2016
 16 S2 p. S77-S78
2 p.
 artikel
17 A Pharmacokinetic/Pharmacodynamic Perspective on the Effect of Bruton's Tyrosine Kinase Inhibitors on Collagen-Induced Platelet Aggregation Chen, Jun
 2016
 16 S2 p. S121-
1 p.
 artikel
18 A Phase 1 Clinical Trial of Cirmtuzumab, a First-in-Class ROR1 Inhibiting Antibody, for the Treatment of Patients with Relapsed or Refractory CLL: Interim Analysis Choi, Michael
 2016
 16 S2 p. S44-
1 p.
 artikel
19 A Phase I/II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy as Frontline Therapy for Older Patients with ALL Short, Nicholas
 2016
 16 S2 p. S15-
1 p.
 artikel
20 A Phase II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy for Patients with Relapsed/Refractory ALL Short, Nicholas
 2016
 16 S2 p. S15-S16
2 p.
 artikel
21 A Phase II Trial of Low-Dose Hypomethylating Agents in Patients with Low- or Intermediate-1-Risk MDS Short, Nicholas
 2016
 16 S2 p. S88-S89
2 p.
 artikel
22 A Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies Lee, Daniel
 2016
 16 S2 p. S24-
1 p.
 artikel
23 A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation Giammarco, Sabrina
 2016
 16 S2 p. S79-
1 p.
 artikel
24 ARV-825, a BRD4 Inhibitor, Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Myeloid Leukemia and Overcomes Stroma Mediated Resistance by Modulating Chemokine Receptor, Cell Adhesion and Metabolic Targets Piya, Sujan
 2016
 16 S2 p. S36-S37
2 p.
 artikel
25 A Single Institution Analysis of Patients with Dual Diagnosis of T-Cell Large Granular Lymphocytic Leukemia and either a Plasma Cell and/or a B-Cell Lymphoproliferative Disorder Van den Bergh, Magali
 2016
 16 S2 p. S117-
1 p.
 artikel
26 ASXL1 Frameshift Mutations Drive Inferior Outcomes in CMML without Negative Impact in MDS Sallman, David
 2016
 16 S2 p. S87-
1 p.
 artikel
27 Attitudes Towards Hematopoietic Stem Cell Transplantation (HSCT) - Differences Between Physicians and Nurses Pasvolsky, Oren
 2016
 16 S2 p. S120-S121
2 p.
 artikel
28 Author Index 2016
 16 S2 p. A7-A14
nvt p.
 artikel
29 A 51 Year Old Man with Hypogammaglobulinemia Secondary to Chronic Lymphocytic Leukemia Receiving fSCIG in the Home Setting Greer, Michelle
 2016
 16 S2 p. S41-
1 p.
 artikel
30 Blinatumomab is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: the Bologna Compassionate Program Experience Papayannidis, Cristina
 2016
 16 S2 p. S14-S15
2 p.
 artikel
31 BRAF and MAP2K1 Genes Mutation in Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia Julhakyan, Hunan
 2016
 16 S2 p. S99-S100
2 p.
 artikel
32 CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes Mathias, Melissa
 2016
 16 S2 p. S8-
1 p.
 artikel
33 Characteristics and Outcomes in Women and Men in the Connect® CLL Registry Bachow, Spencer
 2016
 16 S2 p. S43-S44
2 p.
 artikel
34 Chemotherapy Induced Thrombocytopenia in Children and Young Adults with Hematologic Malignancies Mkhitaryan, Sergey
 2016
 16 S2 p. S126-
1 p.
 artikel
35 Chemotherapy of Primary Mediastinal B-Cell Lymphoma Mangasarova, Jana
 2016
 16 S2 p. S110-
1 p.
 artikel
36 Clinical Characteristics of Patients with Primary or Post-Polycythemia Vera/Post-Essential Thrombocytopenia Myelofibrosis and Deletion 13q Masarova, Lucia
 2016
 16 S2 p. S92-
1 p.
 artikel
37 Clinical Features and Outcomes of Plasmacytoma: a National Cancer Database Study (2000 – 2011) Goyal, Gaurav
 2016
 16 S2 p. S81-S82
2 p.
 artikel
38 Clinical Impact of Underweight on the Outcome of Patients with Acute Myeloid Leukemia: Retrospective Study of JALSG AML201 Harada, Kaito
 2016
 16 S2 p. S19-S20
2 p.
 artikel
39 Clinical Outcome of Acute Lymphocytic Leukemia with Concurrent MLL Gene Rearrangement and t (9; 22) in the Era of Tyrosine Kinase Inhibitors Badar, Talha
 2016
 16 S2 p. S1-
1 p.
 artikel
40 Clinical Response to Total Skin Electron Beam Therapy in Primary Cutaneous T-Cell Lymphoma Dean, Erin
 2016
 16 S2 p. S97-
1 p.
 artikel
41 Clofarabine and Cytarabine Combination in Patients with Fludarabine/Cytarabine Refractory Acute Myeloid Leukemia Tekgündüz, Emre
 2016
 16 S2 p. S24-S25
2 p.
 artikel
42 Clofarabine Plus Cytarabine Therapy in Fludarabine Refractory Acute Leukemia Patients Dogu, Mehmet
 2016
 16 S2 p. S8-S9
2 p.
 artikel
43 Coagulopathy with Chimerism; the Risks of Rituximab Rafei, Hind
 2016
 16 S2 p. S3-
1 p.
 artikel
44 Comparative Value of Post-Remission Treatment in Cytogenetically Normal AML Subclassified by NPM1 and FLT3-ITD Allelic Ratio Versluis, Jurjen
 2016
 16 S2 p. S27-
1 p.
 artikel
45 Comparing Eras in Myelofibrosis: Changing Patterns of Treatment Before and After FDA-Approval of Ruxolitinib Kuykendall, Andrew
 2016
 16 S2 p. S91-S92
2 p.
 artikel
46 Comparison of the Modified Low-Dose Cytarabine with 5-Day Decitabine Therapy for Elderly AML Patients Unfit for Intensive Chemotherapy Cho, Byung Sik
 2016
 16 S2 p. S23-S24
2 p.
 artikel
47 Comparison of Vincristine Pharmacokinetics (PK) in Adolescent/Young Adult (AYA) Versus Younger Patients Defined by Tanner Stage during Treatment for Acute Lymphoblastic Leukemia (ALL) Isenalumhe, Leidy
 2016
 16 S2 p. S16-S17
2 p.
 artikel
48 Complex Karyotype and Low Hypodiploidy/Near Triploidy are Adverse Prognostic Factors in Adult ALL (ALL) Independent of MRD Status Issa, Ghayas
 2016
 16 S2 p. S7-
1 p.
 artikel
49 Cross-Study Multivariable Analysis of the Impact of Adding Rituximab to Venetoclax on the Depth and Durability of Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Tam, Constantine
 2016
 16 S2 p. S51-
1 p.
 artikel
50 Cyclosporine (CsA) Pharmacogenetics Post HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myeloid Leukemia: Value of CYP3A4 Gene Polymorphism El-Beih, Essam
 2016
 16 S2 p. S123-S124
2 p.
 artikel
51 Daratumumab Yields Rapid Hematologic Responses in Patients with Heavily Pretreated, Relapsed AL Amyloidosis Kaufman, Gregory
 2016
 16 S2 p. S75-
1 p.
 artikel
52 Detection of BCR-ABL Kinase Domain Mutations in Chronic Myeloid Leukemia Patients Escobar, Nancy
 2016
 16 S2 p. S60-
1 p.
 artikel
53 Determining Treatment for Older Patients with High-Risk MDS and AML: which Factors Predict Optimal Quality of Life? Tinsley, Sara
 2016
 16 S2 p. S129-
1 p.
 artikel
54 Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL Sethi, Tarsheen
 2016
 16 S2 p. S68-S69
2 p.
 artikel
55 Discordance Between the Prognostic Impact of MIPI and Overall Survival in a Multicenter Cohort of Patients with Mantle Cell Lymphoma Staton, Ashley
 2016
 16 S2 p. S115-
1 p.
 artikel
56 Does Occurrence of Other Malignancy After Essential Thrombocythemia and Polycythemia Vera Influence their Rate of Transformation to Myelofibrosis? Masarova, Lucia
 2016
 16 S2 p. S93-
1 p.
 artikel
57 Does Therapy-Related Myelofibrosis Exist? Analysis of 1100 Myelofibrosis Cases from a Single Institution Masarova, Lucia
 2016
 16 S2 p. S93-
1 p.
 artikel
58 Dropled Digital PCR May Have a Prognostic Value for Predicting Relapse after Imatinib Discontinuation Fava, Carmen
 2016
 16 S2 p. S62-S63
2 p.
 artikel
59 Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant Salem, Rana
 2016
 16 S2 p. S34-S35
2 p.
 artikel
60 Early Complete Response to Corticosteroids in T-Cell Acute Lymphoblastic Leukemia: Report of a Case and Review of the Literature Tavares, Danilo
 2016
 16 S2 p. S16-
1 p.
 artikel
61 Editorial Board/Masthead 2016
 16 S2 p. A3-
1 p.
 artikel
62 Enteroviral Infection in Patients Treated with Rituximab for Non Hodgkin Lymphoma: a Case Series and Review of the Literature Grisariu, Sigal
 2016
 16 S2 p. S103-
1 p.
 artikel
63 Epidemiology of Common Lymphoid Malignancies in the Veteran Health Administration Halwani, Ahmad
 2016
 16 S2 p. S113-
1 p.
 artikel
64 Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma Gavriatopoulou, Maria
 2016
 16 S2 p. S75-
1 p.
 artikel
65 Feasibility of Allogeneic Stem Cell Transplantation After Azacitidine in Patients with High Risk Myelodysplastic Syndromes or Low-Blast Count Acute Myeloid Leukemias: the Experience of the BMT-AZA Multicenter Prospective Study Voso, Maria Teresa
 2016
 16 S2 p. S83-S84
2 p.
 artikel
66 Final Phase IIa Study Results Evaluating the CXCR4 Antagonist BL-8040 in Combination with Cytarabine (Ara-C) for the Treatment of Relapsed/Refractory AML Patients Borthakur, Gautam
 2016
 16 S2 p. S28-
1 p.
 artikel
67 From Human Genetic to Mouse Model: SF3B1 Mutation and its Impact on Chronic Lymphocytic Leukemia Wang, Lili
 2016
 16 S2 p. S52-
1 p.
 artikel
68 Frontline Therapy with Combination of Hyper-CVAD with Ponatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL): A Phase II Study Sasaki, Koji
 2016
 16 S2 p. S10-S11
2 p.
 artikel
69 Gemtuzumab Ozogamicin Produces Durable Responses in Variant Acute Promyelocytic Leukemia with t(11;17) Balakrishnan, Asha
 2016
 16 S2 p. S38-
1 p.
 artikel
70 Generation of a Quantitative Real Time-Polymerase Chain (Q-PCR) Assay to Identify BCR/ABL1-like ALL Cases Chiaretti, Sabina
 2016
 16 S2 p. S5-
1 p.
 artikel
71 Genetic Landscape and Gene Expression Profile of Chronic Lymphocytic Leukemia Patients with Ultra-Stable Disease Del Giudice, Ilaria
 2016
 16 S2 p. S42-S43
2 p.
 artikel
72 Genomic Landscape of Acute Erythroid Leukemia Iacobucci, Ilaria
 2016
 16 S2 p. S26-S27
2 p.
 artikel
73 Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-SCT) with Post-Transplant Cyclophosphamide (Post-Cy) for Haematological Malignancies: A Single Centre Experience Motorin, Dmitry
 2016
 16 S2 p. S20-S21
2 p.
 artikel
74 Hematology Journals Make Poor Use of Reporting Guidelines: 40% Percent Require None at All Wayant, Cole
 2016
 16 S2 p. S127-
1 p.
 artikel
75 Hereditary Hematologic Malignancies: Genetic Counseling Implementation in a Large Leukemia Center Bannon, Sarah
 2016
 16 S2 p. S128-S129
2 p.
 artikel
76 High-Density Neutrophils are Immunosuppressive in Multiple Myeloma Due to Increased Arginase-1, Predictor of Short Progression Free Survival Romano, Alessandra
 2016
 16 S2 p. S69-S70
2 p.
 artikel
77 High Frequency of MTHFR, MTR and TC2 Gene Polymorphisms in Guatemalan Children with ALL Carranza, Claudia
 2016
 16 S2 p. S7-S8
2 p.
 artikel
78 High Throughput Chemical Library Screens Identify a Novel Small Molecule Checkpoint Inhibitor that Activates Anti-myeloma T Cells Driscoll, James J.
 2016
 16 S2 p. S82-
1 p.
 artikel
79 Human Vδ1+ γδ Peripheral T-Cell Lymphoma/Leukemia are Derived from Natural Killer T (NKT) Cells and Might be Treated with Blocking Anti-CD1d Antibody Bachy, Emmanuel
 2016
 16 S2 p. S105-S106
2 p.
 artikel
80 Identifying the Genomic Landscape of Pediatric Myelodysplastic Syndromes (MDS) Schwartz, Jason
 2016
 16 S2 p. S83-
1 p.
 artikel
81 IgVH Genes Somatic Mutations in Splenic Marginal Zone Lymphoma Julhakyan, Hunan
 2016
 16 S2 p. S122-
1 p.
 artikel
82 Imatinib Mesylate as First-line Therapy in Patients with Chronic Myeloid Leukemia Philadelphia + (CML-PH+) in Accelerated Phase (AP), Comparison with Chronic Phase. A Long Term Retrospective Study Vicente-Hernandez, Berenice
 2016
 16 S2 p. S54-
1 p.
 artikel
83 Immune Cell Modulations in Nordic FL Patients After Lenalidomide in the SAKK 35/10 Trial Lockmer, Sandra
 2016
 16 S2 p. S111-S112
2 p.
 artikel
84 Impact of Landmark Responses on 3-Year Outcomes in CP-CML Patients in the Ponatinib PACE Trial Talpaz, Moshe
 2016
 16 S2 p. S61-S62
2 p.
 artikel
85 Impact of Persistent Somatic Mutations on Day 14 After Induction Chemotherapy for Acute Myeloid Leukemia Sweet, Kendra
 2016
 16 S2 p. S38-S39
2 p.
 artikel
86 Impact of the GSTA1 Gene Polymorphism on Clinical Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myeloid Leukemia Saleh, Mostafaf Mohammed
 2016
 16 S2 p. S118-S119
2 p.
 artikel
87 Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: a Single-Center Study at the American University of Beirut Medical Center (AUBMC) Massoud, Radwan
 2016
 16 S2 p. S122-S123
2 p.
 artikel
88 Indications and Outcomes of Allogeneic Stem Cell Transplant for Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors Sweet, Kendra
 2016
 16 S2 p. S65-S66
2 p.
 artikel
89 Inhibition of B-Catenin and Bcr-Abl Tyrosine Kinase Synergistically Targets Blast Crisis CML Cells and Stem/Progenitor Cells In Vitro and In Vivo Carter, Bing
 2016
 16 S2 p. S63-S64
2 p.
 artikel
90 Inhibition OF USP7 Induces Selective Cancer Cell Death in Chronic Lymphocytic Leukemia Carrà, Giovanna
 2016
 16 S2 p. S49-S50
2 p.
 artikel
91 Insights on Treating HCV-Related B Cell Non-Hodgkin Lymphoma Pittella, Ana
 2016
 16 S2 p. S112-S113
2 p.
 artikel
92 International Sentinel Site Surveillance of Patients with Transfusional Hemosiderosis Treated with Deferasirox in Actual Practice Setting El-Beshlawy, Amal
 2016
 16 S2 p. S85-
1 p.
 artikel
93 Leukemization of Follicular Lymphoma: Diagnostic Features and Clinical Course of a Rare Form of the Disease Nesterova, Ekaterina
 2016
 16 S2 p. S111-
1 p.
 artikel
94 Long-Term Follow-Up of Primary Intestinal Aggressive Lymphomas Treated with mNHL-BFM-90 Zvonkov, Evgeniy
 2016
 16 S2 p. S107-
1 p.
 artikel
95 Mechanisms of Resistance to Volasertib and Its Combination Effect with Azacitidine Inacute Myeloid Leukemia (AML) Adachi, Yoshiya
 2016
 16 S2 p. S23-
1 p.
 artikel
96 Metabolism of Membrane Phospholipids in Acute Leukemia and During Chemotherapy Hakobyan, Yervand
 2016
 16 S2 p. S18-
1 p.
 artikel
97 Microsatellite Instability in Chronic Myeloid Leukemia Using D17S261 and D3S643 Markers- a Pilot Study in Western India Patel, Trupti
 2016
 16 S2 p. S54-S55
2 p.
 artikel
98 MRD Detection in Egyptian ALL Patients using IGH/TCR Gene Rearrangements as Targets for Real-Time Quantitative PCR: Single Center Experience Abdelsalam, Eman
 2016
 16 S2 p. S4-S5
2 p.
 artikel
99 Mutant NPM1 MRD and FLT3-ITD Status are Independent Prognostic Factors for the Risk of Relapse in AML Patients Grob, Tim
 2016
 16 S2 p. S31-S32
2 p.
 artikel
100 Myc+ Single-Hit Lymphoma Patients had Benefit from Dose-Intensified Chemotherapy Misyurina, Anna
 2016
 16 S2 p. S109-
1 p.
 artikel
101 Myelodysplastic/Myeloproliferative Neoplasms Unclassified (MDS/MPN-U) Overlap: Impact of Hypomethylating Agents? Hendrix, Kaitlin
 2016
 16 S2 p. S96-
1 p.
 artikel
102 Myelodysplastic Syndromes with Bone Marrow Fibrosis: a Distinct Entity Melody, Megan
 2016
 16 S2 p. S85-S87
3 p.
 artikel
103 Myelotoxicity and Reduction in Number of CD34 + Early Hematopoietic Progenitors in Adult Poor-Prognosis Patients with Diffuse Large B-Cell Lymphoma in Late Period After High-Dose Chemotherapy by mNHL-BFM-90 Dorokhina, Elena
 2016
 16 S2 p. S121-S122
2 p.
 artikel
104 Newly Diagnosed Multiple Myeloma is Associated with Hypercoagulability and High Risk of VTE The ROADMAP Study Fotiou, Despina
 2016
 16 S2 p. S76-S77
2 p.
 artikel
105 Non-Oncogene Addiction to BRD in CLL: from JQ1 Response to Resistence Carrà, Giovanna
 2016
 16 S2 p. S50-
1 p.
 artikel
106 Novel BRD4-Degrading Proteolysis Targeting Chimera (PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma (MCL) Cells Bhalla, Kapil
 2016
 16 S2 p. S108-S109
2 p.
 artikel
107 Ongoing Complete Remissions in ZUMA-1: A Phase 1-2 Multicenter Study of KTE-C19 (Anti-CD19 CAR T Cells) in Patients with Refractory Aggressive B Cell Non-Hodgkin Lymphoma Neelapu, Sattva
 2016
 16 S2 p. S102-
1 p.
 artikel
108 OPTIC-2L: a Superiority Trial of Two Lower Doses of Ponatinib Versus Standard Dose Nilotinib in Second-Line Chronic Phase CML Lipton, Jeffrey
 2016
 16 S2 p. S60-S61
2 p.
 artikel
109 Outcome of Adult Philadelphia Chromosome-Positive ALL in a Cancer Hospital in East India Bhave, Saurabh
 2016
 16 S2 p. S9-
1 p.
 artikel
110 Outcome of Allogeneic Hematopoietic Stem Cell Transplant in Therapy Related Myeloid Neoplasms: Comparative Study with a De Novo Myeloid Neoplasms Group Bermejo, Oscar Ferre
 2016
 16 S2 p. S29-S30
2 p.
 artikel
111 Outcomes after Blinatumomab Failure in Patients with Relapsed/ Refractory (R/R) B-cell ALL (ALL) Yilmaz, Musa
 2016
 16 S2 p. S12-S13
2 p.
 artikel
112 Outcomes in Refractory Aggressive Diffuse Large B Cell Lymphoma (DLBCL): Results from the International SCHOLAR-1 Study Crump, Michael
 2016
 16 S2 p. S101-
1 p.
 artikel
113 Outcomes of Relapsed Core Binding Factor Acute Myeloid Leukemia: an MD Anderson Experience Khan, Maliha
 2016
 16 S2 p. S35-S36
2 p.
 artikel
114 Outcomes with Ibrutinib by Line of Therapy in Patients with CLL: Analyses from Phase 3 Data Reddy, Nishitha
 2016
 16 S2 p. S43-
1 p.
 artikel
115 Overall Survival (OS) of Older Patients with Acute Myeloid Leukemia (AML) and Association with Socioeconomic and Health Care System Factors Bhatt, Vijaya
 2016
 16 S2 p. S21-S22
2 p.
 artikel
116 Overexpression of the Transcription Factor Yin Yang 1 in Non-Hodgkin Lymphoma is associated with Chemo-Immune Resistance Falzone, Luca
 2016
 16 S2 p. S119-S120
2 p.
 artikel
117 Pegfilgrastim 6 mg versus 12 mg for Autologous Stem Cell Mobilization in Multiple Myeloma Patients Matar, Sara
 2016
 16 S2 p. S70-
1 p.
 artikel
118 Phase I trial: CD19-Targeted CAR T-Cells in Patients with Residual CLL Following Initial Purine Analog-Based Therapy Geyer, Mark
 2016
 16 S2 p. S48-
1 p.
 artikel
119 Phase 3 Study of Ibrutinib versus Chlorambucil in Patients ≥65 Years with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Burger, Jan
 2016
 16 S2 p. S45-S46
2 p.
 artikel
120 Phenotypic Profile of Rh and Kell Blood Group Systems in Blood Donors and Patients with Hematologic Malignancies: a Report from Armenia Azizyan, Izabella
 2016
 16 S2 p. S124-S125
2 p.
 artikel
121 Ponatinib Therapy for Philadelphia-Positive ALL (Ph+ ALL) Patients: Real-World Clinical Practice vs the PACE Trial Mauro, Michael
 2016
 16 S2 p. S5-S6
2 p.
 artikel
122 Ponatinib versus Bosutinib in 3rd-Line Chronic Phase - Chronic Myeloid Leukemia (CP-CML): Indirect Comparison of Efficacy Using Iterative Proportional Fitting McGarry, Lisa
 2016
 16 S2 p. S58-S59
2 p.
 artikel
123 Population-Based Cause of Death Among Patients with Myelodysplastic Syndromes Brunner, Andrew
 2016
 16 S2 p. S87-S88
2 p.
 artikel
124 Post Transplant Brentuximab Maintenance Appears more Effective than Post Transplant Salvage Brentuximab for Relapsed /Refractory Hodgkin Lymphoma Chidiac, Amanda
 2016
 16 S2 p. S68-
1 p.
 artikel
125 Preclinical Study of Combination of Antifolate Agents with Palbociclib Isethionate to Treat Mantle Cell Lymphoma with or without P53 Deficiency Wang, Huihan
 2016
 16 S2 p. S99-
1 p.
 artikel
126 Prognostic Index and Nomogram for Overall Survival (OS) of Adult Patients with Philadelphia-negative B-cell ALL Yilmaz, Musa
 2016
 16 S2 p. S13-S14
2 p.
 artikel
127 Prognostic Value of Regulatory T Cells, CD200 and TIM3 Expression in Acute Myeloid Leukemia (AML) Zahran, Asmaa
 2016
 16 S2 p. S33-S34
2 p.
 artikel
128 Propensity Score Analysis: Hyper-CVAD (HCVAD) + Ponatinib vs. HCVAD + Dasatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL) Sasaki, Koji
 2016
 16 S2 p. S9-S10
2 p.
 artikel
129 Prospective Evaluation of Safety and Efficacy of BR Regimen in Previously Untreated CLL Patients Stadnik, Elena
 2016
 16 S2 p. S46-S47
2 p.
 artikel
130 Prospective Trial of Comparision Mobilization Regimens in Patients with Multiple Myeloma before Autologous SCT Motorin, Dmitry
 2016
 16 S2 p. S79-S80
2 p.
 artikel
131 Racial Disparities in Patients with Myelodysplastic Syndrome (MDS): is There Really a Difference? Ramadan, Hanadi
 2016
 16 S2 p. S89-S90
2 p.
 artikel
132 Rapid Achievement of MR4.5 after Switching from Imatinib to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal Ritchie, Ellen
 2016
 16 S2 p. S63-
1 p.
 artikel
133 Real-Life Discontinuation of TKIS Luzi, Debora
 2016
 16 S2 p. S55-
1 p.
 artikel
134 Real Life Experience for Integration of PET-CT in the Treatment of HL in Lebanon Sakr, Riwa
 2016
 16 S2 p. S67-S68
2 p.
 artikel
135 Relevance of Molecular Monitoring of Transcript Level in RUNX1-RUNX1T1 AML Girshova, Larisa
 2016
 16 S2 p. S30-S31
2 p.
 artikel
136 RELINFO - Brazilian Network for Lymphoma Registry in Rio de Janeiro: Preliminary Results Gomes, Leonardo
 2016
 16 S2 p. S108-
1 p.
 artikel
137 RESULTS of High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Pediatric Brain Tumors Gevorgian, Asmik
 2016
 16 S2 p. S118-
1 p.
 artikel
138 Retrospective Cohort Analysis Examining the Efficacy and Safety of (V)DTPACE in Newly Diagnosed and Relapsed/Refractory Myeloma Patients – the UK Experience Sriskandarajah, Priya
 2016
 16 S2 p. S80-
1 p.
 artikel
139 Risk Factors for Graft-Versus-Host Disease after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide McCurdy, Shannon
 2016
 16 S2 p. S125-S126
2 p.
 artikel
140 Role of the Methylenetetrahydrofolate Reductase (MTHFR) A1982C Gene Polymorphism in Predicting Clinical Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantationin Patients with Myeloid Leukemia El Beih, Essam
 2016
 16 S2 p. S22-
1 p.
 artikel
141 Routine CMV Surveillance in Autologous Hematopoietic Cell Transplantation Setting: is It Time for Rethink? Kaya, Ali
 2016
 16 S2 p. S120-
1 p.
 artikel
142 RT-qPCR and RT-Digital PCR: a Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukaemia Alikian, Mary
 2016
 16 S2 p. S55-S56
2 p.
 artikel
143 Serum Albumin as Prognostic Factor for Overall Survival in Rearranged MYC and BCL2/BCL6 Positive Double Hit Diffuse Large B Cell Lymphomas Talati, Chetasi
 2016
 16 S2 p. S99-
1 p.
 artikel
144 Serum Ferritin Levels Prior to Transplantation Might be Used for Predicting the Severity of Transfusional Iron Overload in Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Recipients Sivgin, Serdar
 2016
 16 S2 p. S28-S29
2 p.
 artikel
145 Single-Cell RNA-Seq Allows Deep Analysis of the Tumor Immune Microenvironment and Alterations Induced by Anti-PD-1 Treatment Miller, Brian
 2016
 16 S2 p. S127-
1 p.
 artikel
146 Single Center Experience in Diagnosis of Hepatosplenic T-cell Lymphoma Chernova, Natalya
 2016
 16 S2 p. S100-
1 p.
 artikel
147 Single Institution Experience in Management of Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) Apuri, Susmitha
 2016
 16 S2 p. S98-
1 p.
 artikel
148 Single Institution Experience with G-CSF Mobilized T-Cell Replete Haploidentical Hematopoietic Cell Transplantation Huselton, Eric
 2016
 16 S2 p. S25-S26
2 p.
 artikel
149 Small Fiber Neuropathy is More Frequent in Chronic Lymphocytic Leukemia and NonHodgkin Lymphoma Patients Pamuk, Gulsum Emel
 2016
 16 S2 p. S97-
1 p.
 artikel
150 Somatic Next Generation Sequencing Panels Identify Potentially Pathogenic Germline Variants in Genes Associated with Hereditary Myeloid Malignancies Drazer, Michael
 2016
 16 S2 p. S96-
1 p.
 artikel
151 Stimulation of the B-Cell Receptor (BCR) Induces Tyrosine Phosphorylation of STAT3 via NF-κB Dependent Mechanism Rozovski, Uri
 2016
 16 S2 p. S40-S41
2 p.
 artikel
152 Study of Alteration in Binding Affinity of RUNX1 with DNA because of Mutations Present in Acute Myeloid Leukemia Patients, and Change in its Direct/Indirect Gene Expression Level Zack, Jyoti
 2016
 16 S2 p. S18-S19
2 p.
 artikel
153 Subject Index 2016
 16 S2 p. A15-A17
nvt p.
 artikel
154 Superior Lethal Activity of Novel BRD4-Degrading Proteolysis Targeting Chimera (PROTACs) versus BET Protein Bromodomain Inhibitor (BETi) Against Post-Myeloprofilerative Neoplasm (MPN) Secondary AML Cells Bhalla, Kapil
 2016
 16 S2 p. S93-S94
2 p.
 artikel
155 Survival Comparison Amongst Commonly Used Frontline Regimens in Patients Age 70 Years and Older with Acute Myeloid Leukemia (AML): A Single-Institution Study of Over 600 Patients Dhulipala, Varun
 2016
 16 S2 p. S29-
1 p.
 artikel
156 Survival Impact of Serum Albumin (SA) in Patients with Acquired Immunodeficiency Syndrome (AIDS) Related Non-Hodgkin's Lymphomas Clara, Joseph
 2016
 16 S2 p. S106-S107
2 p.
 artikel
157 Survival Pattern of Hodgkin's Lymphoma Patients in the Last 25 Years in Lebanon Massoud, Marcel
 2016
 16 S2 p. S67-
1 p.
 artikel
158 Systemic AL Amyloidosis Myopathy: Presentation, Diagnostic Pitfalls and Outcome Muchtar, Eli
 2016
 16 S2 p. S80-S81
2 p.
 artikel
159 Table of Contents 2016
 16 S2 p. A4-
1 p.
 artikel
160 Targeting Ibrutinib-Resistant BTK-C481S Mutation with ARQ 531, a Reversible Non-Covalent Inhibitor of BTK Eathiraj, Sudharshan
 2016
 16 S2 p. S47-S48
2 p.
 artikel
161 Targeting Innate and Adaptive Immune Responses for the Treatment of Acute Myeloid Leukemia Przespolewski, Amanda
 2016
 16 S2 p. S128-
1 p.
 artikel
162 Targeting mTOR/PI3K in Primary CNS Lymphoma (PCNSL) Korfel, Agnieszka
 2016
 16 S2 p. S107-S108
2 p.
 artikel
163 T-Cell Large Granular Lymphocyte Proliferation (LGL) in Patients with Myelodysplastic Syndromes (MDS): Not an Innocent Bystander? Roe, Christa
 2016
 16 S2 p. S89-
1 p.
 artikel
164 The BET Bromodomain Inhibitor (BETi) OTX015 (MK-8628) Upregulates miR-96-5p in Diffuse Large B-Cell Lymphomas (DLBCL) Mensah, Afua
 2016
 16 S2 p. S105-
1 p.
 artikel
165 The CXCR4 Downstream Signaling Pathways in Chronic Lymphocytic Leukemia: a Target to Reverse Microenvironment Protection Vitale, Candida
 2016
 16 S2 p. S42-
1 p.
 artikel
166 The Effect of Polycythemia Vera on Hearing Functions Dogan, Esma
 2016
 16 S2 p. S94-S95
2 p.
 artikel
167 The Genetics of Nodal Marginal Zone Lymphoma Spina, Valeria
 2016
 16 S2 p. S102-S103
2 p.
 artikel
168 The High Efficiency of AutoSCT in the Treatment of Refractory Follicular Lymphoma (FL): Results of the First Russian Prospective Study Nesterova, Ekaterina
 2016
 16 S2 p. S110-S111
2 p.
 artikel
169 The Impact of Circulating Plasma Cells at Transplant on Survival in Multiple Myeloma in the Era of Novel Agents Chakraborty, Rajshekhar
 2016
 16 S2 p. S78-
1 p.
 artikel
170 The Impact of Early Transformation in Low-Grade Lymphomas Treated with Anthracycline Based Chemoimmunotherapy Shams, Samantha
 2016
 16 S2 p. S116-
1 p.
 artikel
171 The Importance of CD200 in Differential Diagnosis of Chronic Lymphocytic Leukemia (CLL) and Possible Role of CD200 in Existence of Infection Complications Aywaz, Aline
 2016
 16 S2 p. S40-
1 p.
 artikel
172 The OPTIC Study: a Multi-Center, Randomized Phase 2 Trial with Response-Based Dose Reduction to Evaluate Three Starting Doses of Ponatinib Gutierrez, Valentin García
 2016
 16 S2 p. S59-S60
2 p.
 artikel
173 The PACE Clinical Trial vs The Real-World: Comparison of Ponatinib Prescribing and Duration of Therapy in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients Mauro, Michael
 2016
 16 S2 p. S58-
1 p.
 artikel
174 The Pathophysiologic Role of JunB in Multiple Myeloma Pathogenesis: Focus on Angiogenesis Malvestiti, Stefano
 2016
 16 S2 p. S77-
1 p.
 artikel
175 The Prognostic Value of the Myeloid-Mediated Immunosuppression Marker Arginase-1 in Classic Hodgkin Lymphoma Romano, Alessandra
 2016
 16 S2 p. S66-S67
2 p.
 artikel
176 The Role of Hypomethylating Agents (Hma) in Early Myeloid Relapses After Allogenic Hematopoietic Stem Cell Transplant (HSCT) Cadenas, Félix López
 2016
 16 S2 p. S84-S85
2 p.
 artikel
177 The Simultaneous Blockade of mTOR and Nuclear Transporter Exportin-1 Induces Synergistic Antitumor Effect through Pro-Survival Metabolism in Mantle Cell Lymphoma Sekihara, Kazumasa
 2016
 16 S2 p. S117-S118
2 p.
 artikel
178 Treatment-Free Remission (TFR) Following Frontline or Second-Line Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTfreedom and ENESTop Mahon, François-Xavier
 2016
 16 S2 p. S64-S65
2 p.
 artikel
179 Treatment of Pediatric B-cell Non-Hodgkin Lymphoma in Croatia Roganovic, Jelena
 2016
 16 S2 p. S100-S101
2 p.
 artikel
180 Update: a Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors Menghrajani, Kamal
 2016
 16 S2 p. S95-S96
2 p.
 artikel
181 Updated Results from the Phase II Study of Hyper-CVAD in Combination with Ofatumumab as Frontline Therapy for Adults with CD20 Positive (CD20+) ALL Issa, Ghayas
 2016
 16 S2 p. S6-
1 p.
 artikel
182 Update on Efficacy and Tolerability of Ofatumumab as Front-Line Treatment for Patients with CLL that are Elderly and Have Severe Co-Morbidities and/or Other Malignancies Falchi, Lorenzo
 2016
 16 S2 p. S41-
1 p.
 artikel
183 Update Results of Frontline Therapy with Combination of Hyper-CMAD with Liposomal Vincristine (M) in Patients (Pts) with ALL (ALL) Sasaki, Koji
 2016
 16 S2 p. S11-S12
2 p.
 artikel
184 Up-Regulation of Regulatory T Cells, CD200 and TIM3 Expression in Acute Myeloid Leukemia (AML) Zahran, Asmaa
 2016
 16 S2 p. S32-S33
2 p.
 artikel
185 Utility of Day 14 Bone Marrow Evaluation in Adults with Philadelphia Chromosome-Negative ALL: Relationship with Minimal Residual Disease Status Short, Nicholas
 2016
 16 S2 p. S14-
1 p.
 artikel
186 VEGF, VEGFR2 and GSTM1 Polymorphisms in Outcome of Multiple Myeloma Patients in the Thalidomide Era Brito, Angelo
 2016
 16 S2 p. S70-S71
2 p.
 artikel
187 Venetoclax Plus Rituximab can Achieve Durable Treatment-Free Remission in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Choi, Michael
 2016
 16 S2 p. S50-S51
2 p.
 artikel
188 Ventricular Arrhythmias and Sudden Death in Patients Taking Ibrutinib Lampson, Benjamin
 2016
 16 S2 p. S52-
1 p.
 artikel
189 Virtual Patient Simulation: Improving Management of Polycythemia Vera Patients No Longer Responding to Cytoreductive Therapy Cooper, Simon
 2016
 16 S2 p. S94-
1 p.
 artikel
190 5-year Experience of Oral Deferasirox (Exjade) Use Prior to Transplantation in Patients with Iron Overload that Underwent Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): Retrospective Analysis of a Single Center from Turkey Sivgin, Serdar
 2016
 16 S2 p. S34-
1 p.
 artikel
191 4-Year Results from the Pivotal Phase 2 PACE Trial: Efficacy and Safety in Heavily Pretreated Leukemia Patients Cortes, Jorge
 2016
 16 S2 p. S56-
1 p.
 artikel
                             191 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland